Table V.
Reported potency of CP-4055 versus cytarabine.
| IC50 (nM) | ||||||
|---|---|---|---|---|---|---|
| Cell line | Cytarabine | CP-4055 | Ratio1 | Assay | N | Reference |
| CCRF-CEM | 50 | ND4 | SRB2 | 119 | NCI3 | |
| CCRF-CEM | 40 | 70 | 1.75 | Cell Count | 3 – 4 | Breistol (ref. 10) |
| HL-60(TB) | 200 | ND4 | SRB | 119 | NCI | |
| K-562 | 15849 | 1140 | 0.07 | SRB | 119 | NCI |
| RPMI-8226 | 316228 | 172330 | 0.54 | SRB | 119 | NCI |
| SR | 251 | 973 | 3.87 | SRB | 119 | NCI |
| MOLT-4 | 50 | 2 | 0.04 | SRB | 119 | NCI |
| MOLT-4 | 0.1 | 0.9 | 9 | Cell Count | 3 – 4 | Breistol (ref. 10) |
| U937 | 167 | 710 | 4.25 | ATP | 14 | Current study |
| HL-60 | 2989 | 13387 | 4.48 | ATP | 24 | Current study |
1
Ratio of the IC50 for CP-4055 to that of cytarabine.
2
Sulforhodamine B stain for total protein.
3
National Cancer Institute 60 cell line screen (http:dtp.nci.nih.gov; cytarabine is NSC 63878).
4
Not determined.